SENTIER

Modern data architecture is not a competitive advantage. Reducing the cost of insight is. AI is advancing quickly, and pharma organizations are investing in cloud platforms and centralized data. The mandate is clear: modernize, become data driven, prepare for AI. Warehouses are rebuilt. Governance frameworks are introduced. Semantic layers are defined. AI pilots are launched. It looks like transformation. Now consider a familiar scenario. A brand team asks, “Did our Q3 promotional mix shift prescribing behavior in priority accounts?” What follows is predictable. Marketing mix logic is assembled. Sales activity definitions are reconciled. Claims are aligned to account hierarchies. Field targets are revalidated. Access dynamics are reviewed. Weeks pass before the output earns broad confidence. Six months later, another team raises a related question about targeting strategy. Much of the underlying logic is reconstructed. The same joins. The same business rules. The same reconciliation debates. This is not a tooling problem. It is a reusability problem. Modern architecture integrates data, but it does not automatically stabilize the logic behind it. Productized logic looks different. A governed account hierarchy referenced consistently by marketing mix, targeting, and field analytics. A single definition of “engaged HCP” applied across segmentation, attribution, and ROI analysis. A reusable feature layer where promotional intensity, access friction, and patient flow are calculated once and leveraged across models. When those components are durable, each new use case builds on prior work instead of restarting it. AI will amplify whatever foundation it sits on. If business rules and features are unstable, AI accelerates inconsistency. If they are governed and reusable, AI accelerates execution. The real test of a modern foundation is simple: Is the next commercial question materially easier to answer than the last one? If the answer is yes, you are building infrastructure. If the answer is no, you are funding projects. Over the next few years, competitive advantage in pharma will not come from who pilots the most advanced models. It will come from who reduces the marginal cost of insight across the organization. Modern architecture enables possibility. Reusable logic creates leverage. #PharmaAnalytics #CommercialExcellence #DataProducts #ModernDataArchitecture #AIReady #DecisionIntelligence

Executives think AI is transformative. Teams doing the work are not convinced. A recent survey of 5,000 white collar workers by Section shows the gap clearly. Roughly 40 percent of non managers say AI saves them no time in a typical week, while executives report significant productivity gains. Leaders are measuring aspiration. Teams are measuring friction. Adoption is not a training problem. Adoption is a product signal. If AI creates extra steps, manual checks, and brittle workflows, people quietly stop using it. If AI saves real time, preserves flexibility, and produces consistent answers, people adopt it without being told. Marketing mix optimization is a good example. The traditional workflow is slow and tedious. A business leader requests a scenario. An analyst pulls data. A data scientist runs the model. Results are packaged, reviewed, and sent back. Then the request changes and the cycle restarts. One scenario can take days. We replaced that chain with an agent that executes the workflow end to end. Scenarios now run in minutes, on demand, with consistent outputs. Analyst cycle time dropped by over 90 percent. Adoption went to full usage immediately. No change management. No evangelism. Just utility. The lesson is simple. AI adoption is earned by removing friction in real workflows. Start with narrow, painful, repeatable tasks. Deliver speed and trust. Scale from there. Everything else is theater.

The Unknown is Where Brand Performance Gains Live Sales and marketing leaders have a strong handle on their business. Sales knows the top prescribers and how often they are being called on. Marketing knows the reach of emails, impressions, and site visits. These are the knowns, and capable people manage them every day. The additional twenty to thirty percent gains in brand performance that are possible beyond effective operations will not come from what is already known. They live in the unknown, the answers that siloed data cannot uncover: - Which combinations of tactics actually create incremental new patient starts versus wasted touches - Where promotional dollars are being spent with no measurable return - How reallocating just ten percent of budget could drive outsized brand performance gains - Which customer segments respond to different engagement mixes and which are overserved or underserved - What patterns consistently signal a shift in prescribing behavior before it shows up in sales data - How digital and field activities reinforce each other versus when they cancel each other out Unlocking these answers requires a stronger data foundation. One that unites all promotional and customer engagement interactions into a single view. One that makes investigation, measurement, and modeling possible. And one that enables AI to deliver answers in minutes instead of weeks. The unknown is where brand performance gains live. Find out how SENTIER is helping companies unlock the full potential of their brands through analytic-ready data foundations built for promotional insights. #PharmaAnalytics #BrandPerformance #PromotionalEffectiveness #AnalyticReadyData #OmnichannelEngagement #DataDrivenDecisions

Every organization pays taxes. Some are visible on the balance sheet. Others are hidden in plain sight. Bad data and shallow analytics create one of the most damaging hidden taxes in business. You rarely see the bill, but you feel it in wasted spend, in delayed decisions, and in confident answers that turn out to be wrong. Over time, the costs compound until the gap between potential and actual performance is impossible to ignore. We explore this in our latest article: The Hidden Tax on Bad Data and Shallow Analytics. #PharmaAnalytics #LifeSciences #OmnichannelEngagement #MedicalAffairs #CommercialExcellence

We are not VC or PE backed, and our model is not built around lock-in. It is built around what our clients actually value. We work side by side with our clients, building solutions, transferring knowledge, and strengthening their teams. The more they understand and own their data and analytics, the more impact we can create together. The end goal is not reliance. It is giving clients control over their strategic capabilities so they can move faster and go further with the right partners beside them. This article explains why pharma is moving toward ownership of data and analytics and what that means for the kind of collaboration that actually delivers. #PharmaAnalytics #CommercialExcellence #DataStrategy #AnalyticsLeadership #PharmaInnovation

Three years. That is how long I have seen companies spend trying to build unified, trustworthy data for business critical decisions, only to end up with something rigid, incomplete, or already outdated. It does not have to be this way. We have proven you can deliver fully operationalized, scalable, and documented analytic-ready data in just 10 weeks, with the flexibility and quality needed for initiatives like promotional impact and omnichannel analytics. In my latest article, I break down ✔️ What “doing data wrong” really looks like ✔️ Why traditional approaches waste so much time ✔️ How we help clients move fast without cutting corners #PharmaceuticalIndustry #DataIntegration #CommercialExcellence #OmnichannelEngagement #PromotionalEffectiveness #PharmaLeadership